Pharmacophore mapping and in silico screening to identify new potent leads for A_2A adenosine receptor as antagonists

References

• Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006, 5, 247–264.
   PubMed Web of Science ®Google Scholar
• Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: an overview. Trends Neurosci 2009, 32, 19–29.
   PubMed Web of Science ®Google Scholar
• Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001, 53, 527–552.
   PubMed Web of Science ®Google Scholar
• Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 2000, 362, 364–374.
   PubMed Web of Science ®Google Scholar
• Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001, 24, 31–55.
   PubMed Web of Science ®Google Scholar
• Sawynok J, Liu XJ. Adenosine in the spinal cord and periphery: release and regulation of pain. Prog Neurobiol 2003, 69, 313–340.
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu X, Gebremedhin D, Falck JR, Harder DR, Koehler RC. Interaction of mechanisms involving epoxyeicosatrienoic acids, adenosine receptors, and metabotropic glutamate receptors in neurovascular coupling in rat whisker barrel cortex. J Cereb Blood Flow Metab 2008, 28, 111–125.
   Google Scholar
• Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci 2006, 29, 647–654.
   PubMed Web of Science ®Google Scholar
• Lahiri S, Mitchell CH, Reigada D, Roy A, Cherniack NS. Purines, the carotid body and respiration. Respir Physiol Neurobiol 2007, 157, 123–129.
   Google Scholar
• Basheer R, Strecker RE, Thakkar MM, McCarley RW. Adenosine and sleep-wake regulation. Prog Neurobiol 2004, 73, 379–396.
   PubMed Web of Science ®Google Scholar
• Meng F, Xie GX, Chalmers D, Morgan C, Watson SJ Jr, Akil H. Cloning and expression of the A2a adenosine receptor from guinea pig brain. Neurochem Res 1994, 19, 613–621.
   Google Scholar
• Peterfreund RA, MacCollin M, Gusella J, Fink JS. Characterization and expression of the human A2a adenosine receptor gene. J Neurochem 1996, 66, 362–368.
   PubMed Web of Science ®Google Scholar
• Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, Ijzerman AP, Stevens RC. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322, 1211–1217.
   PubMed Web of Science ®Google Scholar
• Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007, 14, 1315–1323.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson’s disease. Nat Rev Drug Discov 2006, 5, 845–854.
   PubMed Web of Science ®Google Scholar
• Blum D, Hourez R, Galas MC, Popoli P, Schiffmann SN. Adenosine receptors and Huntington’s disease: implications for pathogenesis and therapeutics. Lancet Neurol 2003, 2, 366–374.
   PubMed Web of Science ®Google Scholar
• Satoh S, Matsumura H, Hayaishi O. Involvement of adenosine A2A receptor in sleep promotion. Eur J Pharmacol 1998, 351, 155–162.
   Google Scholar
• Yao L, Arolfo MP, Dohrman DP, Jiang Z, Fan P, Fuchs S, Janak PH, Gordon AS, Diamond I. betagamma Dimers mediate synergy of dopamine D2 and adenosine A2 receptor-stimulated PKA signaling and regulate ethanol consumption. Cell 2002, 109, 733–743.
   Google Scholar
• El Yacoubi M, Ledent C, Parmentier M, Daoust M, Costentin J, Vaugeois J. Absence of the adenosine A(2A) receptor or its chronic blockade decrease ethanol withdrawal-induced seizures in mice. Neuropharmacology 2001, 40, 424–432.
   PubMed Web of Science ®Google Scholar
• Okusa MD, Linden J, Huang L, Rieger JM, Macdonald TL, Huynh LP. A(2A) adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. Am J Physiol Renal Physiol 2000, 279, F809–F818.
   PubMed Web of Science ®Google Scholar
• Gao Z, Li Z, Baker SP, Lasley RD, Meyer S, Elzein E, Palle V, Zablocki JA, Blackburn B, Belardinelli L. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther 2001, 298, 209–218.
   PubMed Web of Science ®Google Scholar
• Schindler CW, Karcz-Kubicha M, Thorndike EB, Müller CE, Tella SR, Ferré S, Goldberg SR. Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists. Br J Pharmacol 2005, 144, 642–650.
   PubMed Web of Science ®Google Scholar
• Varani K, Portaluppi F, Gessi S, Merighi S, Ongini E, Belardinelli L, Borea PA. Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors: functional and biochemical aspects. Circulation 2000, 102, 285–289.
   PubMed Web of Science ®Google Scholar
• Peirce SM, Skalak TC, Rieger JM, Macdonald TL, Linden J. Selective A(2A) adenosine receptor activation reduces skin pressure ulcer formation and inflammation. Am J Physiol Heart Circ Physiol 2001, 281, H67–H74.
   Google Scholar
• Brown RA, Spina D, Page CP. Adenosine receptors and asthma. Br J Pharmacol 2008, 153 Suppl 1, S446–S456.
   PubMed Web of Science ®Google Scholar
• Fozard JR, Ellis KM, Villela Dantas MF, Tigani B, Mazzoni L. Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur J Pharmacol 2002, 438, 183–188.
   PubMed Web of Science ®Google Scholar
• Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, Cronstein BN. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003, 48, 240–247.
   PubMed Web of Science ®Google Scholar
• Sullivan GW, Fang G, Linden J, Scheld WM. A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J Infect Dis 2004, 189, 1897–1904.
   PubMed Web of Science ®Google Scholar
• Odashima M, Bamias G, Rivera-Nieves J, Linden J, Nast CC, Moskaluk CA, Marini M, Sugawara K, Kozaiwa K, Otaka M, Watanabe S, Cominelli F. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 2005, 129, 26–33.
   PubMed Web of Science ®Google Scholar
• Montesinos MC, Gadangi P, Longaker M, Sung J, Levine J, Nilsen D, Reibman J, Li M, Jiang CK, Hirschhorn R, Recht PA, Ostad E, Levin RI, Cronstein BN. Wound healing is accelerated by agonists of adenosine A2 (G alpha s-linked) receptors. J Exp Med 1997, 186, 1615–1620.
   PubMed Web of Science ®Google Scholar
• Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 2007, 35, D198–D201.
   PubMed Web of Science ®Google Scholar
• Okamura T, Kurogi Y, Hashimoto K, Sato S, Nishikawa H, Kiryu K, Nagao Y. Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma. Bioorg Med Chem Lett 2004, 14, 3775–3779.
   PubMedGoogle Scholar
• Okamura T, Kurogi Y, Nishikawa H, Hashimoto K, Fujiwara H, Nagao Y. 1,2,4-Triazolo[5,1-i]purine derivatives as highly potent and selective human adenosine A(3) receptor ligands. J Med Chem 2002, 45, 3703–3708.
   Google Scholar
• Minetti P, Tinti MO, Carminati P, Castorina M, Di Cesare MA, Di Serio S, Gallo G, Ghirardi O, Giorgi F, Giorgi L, Piersanti G, Bartoccini F, Tarzia G. 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. J Med Chem 2005, 48, 6887–6896.
   PubMed Web of Science ®Google Scholar
• Baraldi PG, Fruttarolo F, Tabrizi MA, Preti D, Romagnoli R, El-Kashef H, Moorman A, Varani K, Gessi S, Merighi S, Borea PA. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists. J Med Chem 2003, 46, 1229–1241.
   PubMed Web of Science ®Google Scholar
• Michielan L, Bolcato C, Federico S, Cacciari B, Bacilieri M, Klotz KN, Kachler S, Pastorin G, Cardin R, Sperduti A, Spalluto G, Moro S. Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites. Bioorg Med Chem 2009, 17, 5259–5274.
   PubMed Web of Science ®Google Scholar
• Campbell RM, Cartwright C, Chen W, Chen Y, Duzic E, Fu JM, Loveland M, Manning R, McKibben B, Pleiman CM, Silverman L, Trueheart J, Webb DR, Wilkinson V, Witter DJ, Xie X, Castelhano AL. Selective A1-adenosine receptor antagonists identified using yeast Saccharomyces cerevisiae functional assays. Bioorg Med Chem Lett 1999, 9, 2413–2418.
   PubMed Web of Science ®Google Scholar
• Mantri M, de Graaf O, van Veldhoven J, Göblyös A, von Frijtag Drabbe Künzel JK, Mulder-Krieger T, Link R, de Vries H, Beukers MW, Brussee J, Ijzerman AP. 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem 2008, 51, 4449–4455.
   PubMed Web of Science ®Google Scholar
• Beattie D, Brearley A, Brown Z, Charlton SJ, Cox B, Fairhurst RA, Fozard JR, Gedeck P, Kirkham P, Meja K, Nanson L, Neef J, Oakman H, Spooner G, Taylor RJ, Turner RJ, West R, Woodward H. Synthesis and evaluation of two series of 4′-aza-carbocyclic nucleosides as adenosine A2A receptor agonists. Bioorg Med Chem Lett 2010, 20, 1219–1224.
   Google Scholar
• Duplantier AJ, Bachert EL, Cheng JB, Cohan VL, Jenkinson TH, Kraus KG, McKechney MW, Pillar JD, Watson JW. SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase. J Med Chem 2007, 50, 344–349.
   PubMed Web of Science ®Google Scholar
• Lanier MC, Moorjani M, Luo Z, Chen Y, Lin E, Tellew JE, Zhang X, Williams JP, Gross RS, Lechner SM, Markison S, Joswig T, Kargo W, Piercey J, Santos M, Malany S, Zhao M, Petroski R, Crespo MI, Díaz JL, Saunders J, Wen J, O’Brien Z, Jalali K, Madan A, Slee DH. N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy. J Med Chem 2009, 52, 709–717.
   Google Scholar
• Zhang X, Tellew JE, Luo Z, Moorjani M, Lin E, Lanier MC, Chen Y, Williams JP, Saunders J, Lechner SM, Markison S, Joswig T, Petroski R, Piercey J, Kargo W, Malany S, Santos M, Gross RS, Wen J, Jalali K, O’Brien Z, Stotz CE, Crespo MI, Díaz JL, Slee DH. Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson’s disease. J Med Chem 2008, 51, 7099–7110.
   PubMed Web of Science ®Google Scholar
• Dixon SL, Smondyrev AM, Rao SN. PHASE: a novel approach to pharmacophore modeling and 3D database searching. Chem Biol Drug Des 2006, 67, 370–372.
   PubMed Web of Science ®Google Scholar
• Brooks WH, Daniel KG, Sung SS, Guida WC. Computational validation of the importance of absolute stereochemistry in virtual screening. J Chem Inf Model 2008, 48, 639–645.
   PubMed Web of Science ®Google Scholar
• Mohamadi F, Richards NGJ, Guida WC, Liskamp R, Lipton M, Caufield C, et al. Macromodel – an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Computational Chemistry 1990, 11, 440–467.
   Web of Science ®Google Scholar
• Shivakumar D, Williams J, Wu Y, Damm W, Shelley J, Sherman W. Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field. J Chemical Theory and Computation 2010, 6, 1509–1519.
   PubMed Web of Science ®Google Scholar
• Chang G, Guida WC, Still WC. An internal-coordinate Monte Carlo method for searching conformational space. J American Chemical Society 1989, 111, 4379–4386.
   Web of Science ®Google Scholar
• Goodman JM, Still WC. An unbounded systematic search of conformational space. Journal of Computational Chemistry. 1991, 12, 1110–1117.
   Google Scholar
• Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 2006, 20, 647–671.
   PubMed Web of Science ®Google Scholar
• Chen X, Rusinko A, Young SS. Recursive Partitioning Analysis of a Large Structureâ^’Activity Data Set Using Three-Dimensional Descriptors1. J Chem Inf Comput Sci 1998, 38, 1054–1062.
   Google Scholar
• Chen X, Rusinko A 3rd, Tropsha A, Young SS. Automated pharmacophore identification for large chemical data sets. J Chem Inf Comput Sci 1999, 39, 887–896.
   Google Scholar
• Lather V, Kristam R, Saini JS, Karthikeyan NA, Balaji VN. QSAR Models for Prediction of Glycogen Synthase Kinase-3β Inhibitory Activity of Indirubin Derivatives. QSAR & Combinatorial Science 2008, 27, 718–728.
   Google Scholar
• Hansch C, Muir R, Fujita T, Maloney P, Geiger F, Streich M. The Correlation of Biological Activity of Plant Growth Regulators and Chloromycetin Derivatives with Hammett Constants and Partition Coefficients. J American Chemical Society 1963, 85, 2817–2824.
   Web of Science ®Google Scholar
• Narkhede SS, Degani MS. Pharmacophore Refinement and 3D-QSAR Studies of Histamine H3 Antagonists. QSAR & Combinatorial Science 2007, 26, 744–753.
   Google Scholar
• Telvekar VN, Kundaikar HS, Patel KN, Chaudhari HK. 3-D QSAR and Molecular Docking Studies on Aryl Benzofuran-2-yl Ketoxime Derivatives as Candida albicans N-myristoyl transferase Inhibitors. QSAR & Combinatorial Science 2008, 27, 1193–1203.
   Google Scholar
• Bag S, Tawari NR, Degani MS. Insight into Inhibitory Activity of Mycobacterial Dihydrofolate Reductase Inhibitors by In-silico Molecular Modeling Approaches. QSAR & Combinatorial Science 2009, 28, 296–311.
   Google Scholar
• Shoichet BK. Virtual screening of chemical libraries. Nature 2004, 432, 862–865.
   PubMed Web of Science ®Google Scholar
• Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004, 47, 1739–1749.
   PubMed Web of Science ®Google Scholar
• Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004, 47, 1750–1759.
   PubMed Web of Science ®Google Scholar
• Almerico AM, Tutone M, Lauria A. 3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors. Eur J Med Chem 2010, 45, 4774–4782.
   PubMed Web of Science ®Google Scholar
• Tawari NR, Degani MS. Pharmacophore mapping and electronic feature analysis for a series of nitroaromatic compounds with antitubercular activity. J Comput Chem 2010, 31, 739–751.
   PubMed Web of Science ®Google Scholar
• Rajender PS, Vasavi M, Vuruputuri U. Identification of novel selective antagonists for cyclin C by homology modeling and virtual screening. Int J Biol Macromol 2011, 48, 292–300.
   PubMed Web of Science ®Google Scholar
• Pawar V, Lokwani D, Bhandari S, Mitra D, Sabde S, Bothara K, Madgulkar A. Design of potential reverse transcriptase inhibitor containing Isatin nucleus using molecular modeling studies. Bioorg Med Chem 2010, 18, 3198–3211.
   PubMed Web of Science ®Google Scholar
• Reddy AS, Pati SP, Kumar PP, Pradeep HN, Sastry GN. Virtual screening in drug discovery – a computational perspective. Curr Protein Pept Sci 2007, 8, 329–351.
   PubMed Web of Science ®Google Scholar
• Yang SY. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 2010, 15, 444–450.
   PubMed Web of Science ®Google Scholar